Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Barriers to immune cell infiltration in tumors.
Melssen MM, Sheybani ND, Leick KM, Slingluff CL Jr. Melssen MM, et al. J Immunother Cancer. 2023 Apr;11(4):e006401. doi: 10.1136/jitc-2022-006401. J Immunother Cancer. 2023. PMID: 37072352 Free PMC article. Review.
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr. Melssen MM, et al. J Immunother Cancer. 2019 Jun 27;7(1):163. doi: 10.1186/s40425-019-0625-x. J Immunother Cancer. 2019. PMID: 31248461 Free PMC article. Clinical Trial.
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL Jr. Pollack KE, et al. Among authors: melssen mm. J Immunother Cancer. 2020 Apr;8(1):e000544. doi: 10.1136/jitc-2020-000544. J Immunother Cancer. 2020. PMID: 32350119 Free PMC article.
Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.
Melssen MM, Pollack KE, Meneveau MO, Smolkin ME, Pinczewski J, Koeppel AF, Turner SD, Sol-Church K, Hickman A, Deacon DH, Petroni GR, Slingluff CL Jr. Melssen MM, et al. Cancer Immunol Immunother. 2021 Aug;70(8):2151-2164. doi: 10.1007/s00262-020-02844-w. Epub 2021 Jan 16. Cancer Immunol Immunother. 2021. PMID: 33454795 Free PMC article. Clinical Trial.
Vaccine Strategy in Melanoma.
Kwak M, Leick KM, Melssen MM, Slingluff CL Jr. Kwak M, et al. Among authors: melssen mm. Surg Oncol Clin N Am. 2019 Jul;28(3):337-351. doi: 10.1016/j.soc.2019.02.003. Epub 2019 Apr 15. Surg Oncol Clin N Am. 2019. PMID: 31079792 Free PMC article. Review.
Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells.
Melssen MM, Lindsay RS, Stasiak K, Rodriguez AB, Briegel AM, Cyranowski S, Rutkowski MR, Conaway MR, Melief CJM, van der Burg SH, Eyo U, Slingluff CL Jr, Engelhard VH. Melssen MM, et al. Cancer Immunol Res. 2021 May;9(5):583-597. doi: 10.1158/2326-6066.CIR-20-0427. Epub 2021 Feb 22. Cancer Immunol Res. 2021. PMID: 33619119 Free PMC article.
15 results